NASDAQ: AKBA

Akebia Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2022.

If you purchased Akebia securities during the Class Period and would like to join the action, please click “Join This Class Action.”

Class Period:June 28, 2018 to September 2, 2020

If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented;
as a result, Defendants overstated the PRO2TECT Program’s clinical prospects;
accordingly, Defendants also overstated vadadustat’s overall commercial and regulatory prospects; and
as a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Akebia Therapeutics, Inc.

Details of the case:

Why Rosen Law